ECM
SLDB icon

Endurant Capital Management’s Solid Biosciences SLDB Stock Holding History

Endurant Capital Management’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,045
Closed -$346K – 71
2020
Q4 		$346K Buy
+3,045
New +$193K 0.12% 51

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Endurant Capital Management's SLDB Position: Q1 2021 in Review

Endurant Capital Management sold out of Solid Biosciences (SLDB) in Q1 2021, closing a stake of 3,045 shares — an estimated $346K sold.

Endurant Capital Management first reported a position in SLDB in Q4 2020 and held it in 1 quarter. The position peaked at $346K in Q4 2020. 104 funds tracked by Wall St. Rank hold SLDB as of Q1 2021.

  • Endurant Capital Management reported no remaining Solid Biosciences position as of Q1 2021 after selling out during the quarter.
  • Endurant Capital Management sold 3,045 Solid Biosciences shares in Q1 2021, an estimated $346K.
  • Endurant Capital Management first reported a position in Solid Biosciences in Q4 2020 and held it in 1 quarter.
  • Endurant Capital Management's Solid Biosciences position peaked at $346K in Q4 2020.
  • 104 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2021.

Based on Endurant Capital Management's 13F filing for Q1 2021, filed 17 May 2021.